Skip to main content
Top
Published in: BMC Public Health 1/2018

Open Access 01-12-2018 | Research article

Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural India

Authors: Devarsetty Praveen, David Peiris, Stephen MacMahon, Kishor Mogulluru, Arvind Raghu, Anthony Rodgers, Shailaja Chilappagari, Dorairaj Prabhakaran, Gari D. Clifford, Pallab K. Maulik, Emily Atkins, Rohina Joshi, Stephane Heritier, Stephen Jan, Anushka Patel

Published in: BMC Public Health | Issue 1/2018

Login to get access

Abstract

Background

Non-optimal blood pressure (BP) levels are a major cause of disease burden globally. We describe current BP and treatment patterns in rural India and compare different approaches to BP lowering in this setting.

Methods

All individuals aged ≥40 years from 54 villages in a South Indian district were invited and 62,194 individuals (84%) participated in a cross-sectional study. Individual 10-year absolute cardiovascular disease (CVD) risk was estimated using WHO/ISH charts. Using known effects of treatment, proportions of events that would be averted under different paradigms of BP lowering therapy were estimated.

Results

After imputation of pre-treatment BP levels for participants on existing treatment, 76·9% (95% confidence interval, 75.7–78.0%), 5·3% (4.9–5.6%), and 17·8% (16.9–18.8%) of individuals had a 10-year CVD risk defined as low (< 20%), intermediate (20–29%), and high (≥30%, established CVD, or BP > 160/100 mmHg), respectively. Compared to the 19.6% (18.4–20.9%) of adults treated with current practice, a slightly higher or similar proportion would be treated using an intermediate (23·2% (22.0–24.3%)) or high (17·9% (16.9–18.8%) risk threshold for instituting BP lowering therapy and this would avert 87·2% (85.8–88.5%) and 62·7% (60.7–64.6%) more CVD events over ten years, respectively. These strategies were highly cost-effective relative to the current practice.

Conclusion

In a rural Indian community, a substantial proportion of the population has elevated CVD risk. The more efficient and cost-effective clinical approach to BP lowering is to base treatment decisions on an estimate of an individual’s short-term absolute CVD risk rather than with BP based strategy.

Clinical trial registration

Clinical Trials Registry of India CTRI/​2013/​06/​003753, 14 June 2013.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–128.CrossRef Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–128.CrossRef
2.
go back to reference Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press on behalf of the World Health Organization and the World Bank; 1996. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press on behalf of the World Health Organization and the World Bank; 1996.
3.
go back to reference World Health Organisation. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011. World Health Organisation. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011.
4.
go back to reference Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project populations. Lancet. 2000;355:675–87.CrossRef Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project populations. Lancet. 2000;355:675–87.CrossRef
5.
go back to reference Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004;109:1101–7.CrossRef Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004;109:1101–7.CrossRef
6.
go back to reference Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet. 2005;366:1744–9.CrossRef Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet. 2005;366:1744–9.CrossRef
7.
go back to reference Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94:16–26.CrossRef Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94:16–26.CrossRef
8.
go back to reference Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25:73–9.CrossRef Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25:73–9.CrossRef
9.
go back to reference Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60.CrossRef Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60.CrossRef
10.
go back to reference Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag. 2007;3:783–95. Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag. 2007;3:783–95.
12.
go back to reference Williams B, Poulter NR, Brown MJ, et al. British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328:634–40.CrossRef Williams B, Poulter NR, Brown MJ, et al. British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328:634–40.CrossRef
13.
go back to reference Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320:709–10.CrossRef Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320:709–10.CrossRef
14.
go back to reference Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health. 2003;57:634–8.CrossRef Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health. 2003;57:634–8.CrossRef
15.
go back to reference Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013.
16.
go back to reference Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701.CrossRef Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701.CrossRef
18.
go back to reference Praveen D, Patel A, McMahon S, et al. A multifaceted strategy using mobile technology to assist rural primary healthcare doctors and frontline health workers in cardiovascular disease risk management: protocol for the SMARTHealth India cluster randomised controlled trial. Implementation science. 2013;8:137.CrossRef Praveen D, Patel A, McMahon S, et al. A multifaceted strategy using mobile technology to assist rural primary healthcare doctors and frontline health workers in cardiovascular disease risk management: protocol for the SMARTHealth India cluster randomised controlled trial. Implementation science. 2013;8:137.CrossRef
19.
go back to reference Mendis S, Lindholm LH, Anderson SG, et al. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. J Clin Epidemiol. 2011;64:1451–62.CrossRef Mendis S, Lindholm LH, Anderson SG, et al. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. J Clin Epidemiol. 2011;64:1451–62.CrossRef
20.
go back to reference Directorate General of Health Services. Ministry of Health and Family Welfare. Govt. of India. National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke: Operational Guidelines, 2010. URL: http:// health.bih.nic.in/Docs/Guidelines-NPCDCS.pdf [Accessed: 18 March 2014]. Directorate General of Health Services. Ministry of Health and Family Welfare. Govt. of India. National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke: Operational Guidelines, 2010. URL: http:// health.​bih.​nic.​in/Docs/Guidelines-NPCDCS.pdf [Accessed: 18 March 2014].
21.
go back to reference Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRef Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRef
22.
go back to reference Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61:309–18.CrossRef Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61:309–18.CrossRef
23.
go back to reference Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk - overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2305–14.CrossRef Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk - overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2305–14.CrossRef
24.
go back to reference Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels - overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2296–304.CrossRef Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels - overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2296–304.CrossRef
25.
go back to reference Sundstrom J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591–8.CrossRef Sundstrom J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591–8.CrossRef
26.
go back to reference Rachana PR, Anuradha HV, Shivamurthy MC. Anti Hypertensive Prescribing Patterns and Cost Analysis for Primary Hypertension: A Retrospective Study. J Clin Diagn Res. 2014;8(9):HC19–22. Rachana PR, Anuradha HV, Shivamurthy MC. Anti Hypertensive Prescribing Patterns and Cost Analysis for Primary Hypertension: A Retrospective Study. J Clin Diagn Res. 2014;8(9):HC19–22.
27.
go back to reference Srivastava A, Mohanty SK. Age and sex pattern of cardiovascular mortality, hospitalisation and associated cost in India. PLoS One. 2013;8:e62134.CrossRef Srivastava A, Mohanty SK. Age and sex pattern of cardiovascular mortality, hospitalisation and associated cost in India. PLoS One. 2013;8:e62134.CrossRef
28.
go back to reference Gupta R. Coronary Heart Disease in India: Absolute Numbers and Economic Burden. BMJ. 2004. Rapid Response. Gupta R. Coronary Heart Disease in India: Absolute Numbers and Economic Burden. BMJ. 2004. Rapid Response.
32.
go back to reference Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–24.CrossRef Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–24.CrossRef
35.
go back to reference Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371:818–27.CrossRef Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371:818–27.CrossRef
36.
go back to reference Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ. 2000;320:680–5.CrossRef Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ. 2000;320:680–5.CrossRef
37.
go back to reference Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Bmj. 2000;320:705–8.CrossRef Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Bmj. 2000;320:705–8.CrossRef
38.
go back to reference Rodgers A, Lawes CMM, Gaziano T, Vos T. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight. In: Jamison TD, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries Washington (DC): World Bank, The International Bank for Reconstruction and Development/The World Bank Group; 2006. Rodgers A, Lawes CMM, Gaziano T, Vos T. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight. In: Jamison TD, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries Washington (DC): World Bank, The International Bank for Reconstruction and Development/The World Bank Group; 2006.
39.
go back to reference Joshi R, Chow CK, Raju PK, et al. Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India. Circulation. 2009;119:1950–5.CrossRef Joshi R, Chow CK, Raju PK, et al. Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India. Circulation. 2009;119:1950–5.CrossRef
Metadata
Title
Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural India
Authors
Devarsetty Praveen
David Peiris
Stephen MacMahon
Kishor Mogulluru
Arvind Raghu
Anthony Rodgers
Shailaja Chilappagari
Dorairaj Prabhakaran
Gari D. Clifford
Pallab K. Maulik
Emily Atkins
Rohina Joshi
Stephane Heritier
Stephen Jan
Anushka Patel
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2018
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-018-6142-x

Other articles of this Issue 1/2018

BMC Public Health 1/2018 Go to the issue